Romidepsin Plus 3BNC117 Phase 2a Study (ROADMAP)

• ClinicalTrials.gov Identifier: NCT02850016
• Recruitment Status: Completed
• First Posted: July 29, 2016
• Results First Posted: July 14, 2022
• Last Update Posted: July 14, 2022
• Sponsor: Rockefeller University
• Collaborators: University Hospital of Cologne; Aarhus University Hospital
• Information provided by (Responsible Party): Rockefeller University

Study Description

Brief Summary:

The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.

Condition or disease	Intervention/treatment	Phase
Human Immunodeficiency Virus (HIV)	Drug: 3BNC117; Drug: Romidepsin	Phase 2

Detailed Description:

This is a randomized interventional phase 2a trial of 3BNC117 and romidepsin in human immunodeficiency (HIV-1) infected patients on ART, conducted as a multi-center study at the Department of Infectious Diseases, Aarhus University Hospital, Denmark, the Rockefeller University Hospital, USA, and the University Hospital of Cologne, Germany.

Participants will be randomized 1:1 in a non-blinded fashion to receive one of two regimens:

A) Two treatment cycles each consisting of one 3BNC117 infusion (30mg/kg) + three romidepsin infusions (5mg/m2); or

B) Two treatment cycles each consisting of three romidepsin infusions (5mg/m2).

ART will be discontinued 16 weeks after the start of the second treatment cycle (analytical treatment interruption, ATI) and subjects will be monitored weekly for safety and viral rebound. The targeted enrollment is 30 subjects (15 per arm).

Leukapheresis will be performed before and after the two treatment cycles to guarantee sufficient material to investigate changes in the reservoir after the interventions.

The following criteria will require resumption of ART:

• CD4+ T cell-count <350 cells/mm³ (confirmed by repeat measurement)
• 2 consecutive plasma HIV-1 RNA measurements ≥ 200 copies/mL or above their setpoint viremia (if documented)
• Subject request
• Continued ART interruption will, in the opinion of the investigator or study advisers, pose an unacceptable risk to the subject.

If HIV-1 RNA remains undetectable at week 36, subjects will be offered to continue off ART with close monitoring, in conjunction with the subject's primary medical provider, as long as HIV-1 viral rebound does not occur. ART resumption will follow same criteria as detailed above. All subjects will be followed for a total of 48 weeks from enrollment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 48 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)
• Actual Study Start Date: January 6, 2017
• Actual Primary Completion Date: December 31, 2020
• Actual Study Completion Date: December 31, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group A; Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .	Drug: 3BNC117; Intravenous Infusion of 3BNC117; Other Name: Monoclonal Antibody; Drug: Romidepsin; Intravenous Infusion of Romidepsin; Other Name: HDAC inhibitor
Experimental: Group B; Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .	Drug: Romidepsin; Intravenous Infusion of Romidepsin; Other Name: HDAC inhibitor

Outcome Measures

Primary Outcome Measures :

1. Days to Viral Rebound During Analytical Treatment Interruption (ATI) [ Time Frame: Week 24 to Week 36 ]
   Viral rebound is defined as HIV-1 RNA ≥ 200 copies/mL on 2 consecutive measurements during ATI. If viral rebound occurs, the date of the first measurement of HIV-1 RNA ≥ 200 copies/mL will be defined as "date of viral rebound

Secondary Outcome Measures :

1. Number of of Adverse Events (AE), Serious Adverse Events (SAE), and Serious Unexpected Serious Adverse Reactions (SUSAR). [ Time Frame: 48 weeks ]
   The occurrence of adverse events was assessed during each follow up visit. Adverse events of grades 1 or higher were reported.
2. Change in the Size of the Proviral HIV-1 Reservoir [ Time Frame: baseline and week 24 ]
   Determined by total HIV-1 DNA and episomal HIV-1 DNA (2-LTR) in circulating total CD4+ T cells at baseline and prior to the ATI period (week 24).
3. Plasma HIV-1 RNA [ Time Frame: 48 weeks ]
   As measured by a routine clinical assay (Cobas Taqman; detection limit 20 copies/mL), a transcription mediated amplification (TMA)-based assay (detection limit 12 copies/ml) and/or a single copy assay (detection limit 1-2 copies/mL)

Other Outcome Measures:

1. HIV-1 Transcriptional Activity as Determined by Unspliced HIV-1 RNA (CA usHIV-1 RNA) in Circulating Total CD4+ T Cells. [ Time Frame: baseline and week 24 ]
   The median fold-change in cell-associated unspliced HIV-1 RNA concentrations after romidepsin administration across all infusions

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Adults age 18-65 years with documented HIV-1 infection
• CD4+ T-cell count >500 cells/mm3 at screening
• On ART for a minimum of 24 months and HIV-1 RNA plasma level of < 50 copies/ml by standard assays for at least 18 months (a single viral load measurement > 50 but < 500 copies/ml during this time period is allowable).
• Individuals on protease inhibitor or NNRTI-based regimens, or regimens containing cobicistat must be willing to switch to an integrase-inhibitor-based regimen (raltegravir or dolutegravir) prior to enrollment.

Exclusion Criteria:

• Use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the investigators within the last 6 months
• Pregnancy as determined by a positive urine or serum beta-hCG.
• Participant unwilling to use two reliable contraception methods (i.e. condom with spermicide, diaphragm with spermicide, progestin-only containing intrauterine device (IUD) (eg, Mirena, Implanon, Nuva Ring), non-estrogen containing formulations of hormonal birth control drugs with condom) for the study duration.
• Currently breast-feeding.
• History of resistance to 2 or more classes of antiretroviral medications
• Any medical, psychiatric, social, or occupational condition that, as judged by the investigators, would interfere with the evaluation of study objectives (such as severe alcohol or drug abuse, dementia).
• Acute or chronic hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
• A history of AIDS-defining illness within 3 years prior to enrollment.
• History of B-cell lymphoma, including CNS lymphoma
• CD4 nadir < 200 cells/mm3
• History of significant coronary artery disease, myocardial infarction, percutaneous coronary intervention with placement of cardiac stents, or family history of sudden death at age < 50 years.
• ECG at screening that shows QTc >450 msec when calculated using the Fridericia formula from either lead V3 or V4, pathological Q-waves (Q-wave > 40 msec or depth > 0.4-0.5 mV), evidence of a ventricular pre-excitation syndromes, complete or incomplete LBBB or RBBB, second or third degree heart block, QRS duration > 120 msec, or bradycardia defined by sinus rate < 50 bps
• Use of QT-prolonging medication, renal or hepatic disease, structural heart disease or left ventricular dysfunction
• Any symptomatic or asymptomatic arrhythmia excluding sinus arrhythmia and bradycardia ≥ 50 bps.

• Laboratory abnormalities in the parameters listed below:

  1. Absolute neutrophil count ≤ 1,000 cells/μl
  2. Hemoglobin < 11 gm/dL
  3. Platelet count < 125,000 cells/μl
  4. Alanine Aminotransferase (ALT) ≥ 1.25 x ULN
  5. Aspartate Aminotransferase (AST) ≥ 1.25 x ULN
  6. Total bilirubin > 1.0 ULN
  7. Creatinine > 1.0 ULN
• Any vaccination within 14 days prior to 3BNC117 administration
• Receipt of any therapeutic HIV vaccine in the past
• Receipt of any monoclonal antibody or HDAC inhibitor of any kind in the past.
• Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

Contacts and Locations

Locations

United States, New York

The Rockefeller University

New York, New York, United States, 10065

Denmark

Aarhus University Hospital

Aarhus, Denmark

Germany

University of Cologne

Cologne, Germany, 50937

Sponsors and Collaborators

Rockefeller University

University Hospital of Cologne

Aarhus University Hospital

Investigators

• Principal Investigator: Marina Caskey, MD; Rockefeller University

  Study Documents (Full-Text)

Documents provided by Rockefeller University:

Study Protocol and Statistical Analysis Plan  [PDF] October 10, 2017

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Gruell H, Gunst JD, Cohen YZ, Pahus MH, Malin JJ, Platten M, Millard KG, Tolstrup M, Jones RB, Conce Alberto WD, Lorenzi JCC, Oliveira TY, Kummerle T, Suarez I, Unson-O'Brien C, Nogueira L, Olesen R, Ostergaard L, Nielsen H, Lehmann C, Nussenzweig MC, Fatkenheuer G, Klein F, Caskey M, Sogaard OS. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe. 2022 Mar;3(3):e203-e214. doi: 10.1016/S2666-5247(21)00239-1. Epub 2022 Jan 24.

Valente PK, Wu Y, Cohen YZ, Caskey M, Meyers K. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. Clin Trials. 2021 Feb;18(1):17-27. doi: 10.1177/1740774520948042. Epub 2020 Aug 24.

• Responsible Party: Rockefeller University
• ClinicalTrials.gov Identifier: NCT02850016
• Other Study ID Numbers: MCA-0896
• First Posted: July 29, 2016
• Results First Posted: July 14, 2022
• Last Update Posted: July 14, 2022
• Last Verified: July 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Rockefeller University:

Romidepsin; 3BNC117; Broadly neutralizing antibody

Additional relevant MeSH terms:

Acquired Immunodeficiency Syndrome; HIV Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Romidepsin; Histone Deacetylase Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action